Although endocrine therapy using tamoxifen or aromatase blockers is a firm part of hormone receptor–positive breast cancer, no randomized studies could be found addressing the effect of these adjuvant therapies for the situation of advanced breast cancer with brain metastases. This evidence concerns the gene NR4A1 and breast carcinoma.